NEW YORK, September 29, 2015 /PRNewswire via COMTEX/ -- /PRNewswire/ -- Technical Report on-biotechnology Stock Equity Research Institute has initiated coverage buy rating on the following equity ZIOPHARM Oncology Inc. ZIOP,
Complete Phase 2 Data :
NEW YORK, NY / ACCESSWIRE / September 23, 2015 / Vascular Biogenics Ltd., (VBLT) a late-stage clinical biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, recently announced that complete Phase 2 data on VB-111 in combintionwith Bevacizumab (Avastin) will be presented at the European Society for Medical Oncology's (ESMO) European Cancer Congress 2015, being held September 25th-29th in Vienna, Austria Less
great link andat this price someone going to grab this baby up!
NFLX has all the rights, owns the market
Sentiment: Strong Buy
GoPro starts taking applications for $15,000 new virtual reality device LINK
The Associated Press
NEW YORK (AP) — GoPro has begun taking applications from media companies, filmmakers and otherprofessionals to buy its $15,000 virtual reality filming device.
( This Biotech Will Get Sickle Cell Approved, Has 18 Drug Approvals, BLUE None. )
See it Market
This Week In IPOs: “Risk-Off”, Boutique Investment Banking And Sickle Cell Disease
August 10, 2015 Investing Research
( GBT )
GBT is developing the initial product candidate, GBT440, as a once-daily, oral prophylactic therapy for sickle cell disease.GBT plans to explore the treatment of more indications, notably hypoxemic pulmonary disorders and hereditary angioedema.
Highlights. Sickle Cell Disease ,Severe disease with major unmet medical need, large marketopportunity. Highly experience team with successful track record in developing and commercializing drugs. Co. has contributed to 18 drug approvals
Baker Bros. Advisors Boosts Stake In Aquinox Pharmaceuticals Inc. (AQXP) to 39.8%
By Gene Guzun in Hedge Funds,NewsPublished: August 11, 2015
will sell in $60's
you sound scared and should be,earnings up 5x's in just a year -incredible growth